Calidi Biotherapeutics, Inc. SEC filings CLDWW
Calidi Biotherapeutics, Inc. has 406 filings in SEC EDGAR's recent list, going back to May 17, 2021. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 25, 2026 (listing notice, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Sep 17, 2026 | — |
| 424B5 | Prospectus supplement | Mar 9, 2026 | — |
| 424B5 | Prospectus supplement | Mar 6, 2026 | — |
| S-3MEF | Filing | Mar 5, 2026 | — |
| 424B4 | Prospectus | Aug 21, 2025 | — |
| S-1 | Registration statement | Aug 15, 2025 | — |
| S-3 | Shelf registration | Jul 18, 2025 | — |
| 424B3 | Prospectus | Jul 10, 2025 | — |
| 424B3 | Prospectus | Jul 10, 2025 | — |
| S-1 | Registration statement | Jul 3, 2025 | — |
| 424B5 | Prospectus supplement | Mar 31, 2025 | — |
| 424B5 | Prospectus supplement | Feb 5, 2025 | — |
| S-3 | Shelf registration | Jan 10, 2025 | — |
| 424B5 | Prospectus supplement | Jan 10, 2025 | — |
| 424B5 | Prospectus supplement | Jan 8, 2025 | — |
| S-1 | Registration statement | Dec 12, 2024 | — |
| 424B5 | Prospectus supplement | Nov 29, 2024 | — |
| 424B5 | Prospectus supplement | Nov 15, 2024 | — |
| 424B5 | Prospectus supplement | Nov 14, 2024 | — |
| 424B5 | Prospectus supplement | Oct 24, 2024 | — |
| 424B5 | Prospectus supplement | Oct 23, 2024 | — |
| 424B5 | Prospectus supplement | Oct 11, 2024 | — |
| S-3/A | Filing | Oct 7, 2024 | — |
| S-3 | Shelf registration | Oct 1, 2024 | — |
| S-8 | Employee stock plan registration | Oct 1, 2024 | — |
| 424B3 | Prospectus | Jun 4, 2024 | — |
| 424B3 | Prospectus | May 16, 2024 | — |
| 424B4 | Prospectus | Apr 17, 2024 | — |
| S-1/A | Amended registration statement | Apr 15, 2024 | — |
| S-1/A | Amended registration statement | Apr 8, 2024 | — |
| S-1/A | Amended registration statement | Apr 2, 2024 | — |
| S-1/A | Amended registration statement | Apr 1, 2024 | — |
| 424B3 | Prospectus | Mar 12, 2024 | — |
| 424B3 | Prospectus | Mar 1, 2024 | — |
| 424B3 | Prospectus | Feb 12, 2024 | — |
| S-1/A | Amended registration statement | Feb 7, 2024 | — |
| 424B3 | Prospectus | Feb 1, 2024 | — |
| S-1 | Registration statement | Jan 29, 2024 | — |
| 424B3 | Prospectus | Jan 23, 2024 | — |
| S-1/A | Amended registration statement | Jan 16, 2024 | — |
| S-1/A | Amended registration statement | Jan 8, 2024 | — |
| S-1/A | Amended registration statement | Dec 12, 2023 | — |
| S-1 | Registration statement | Oct 6, 2023 | — |
| 424B3 | Prospectus | Aug 4, 2023 | — |
| S-4/A | Filing | Aug 2, 2023 | — |
| S-4/A | Filing | Aug 1, 2023 | — |
| S-4/A | Filing | Jul 25, 2023 | — |
| S-4/A | Filing | Jul 3, 2023 | — |
| S-4/A | Filing | May 9, 2023 | — |
| S-4/A | Filing | Apr 13, 2023 | — |
| S-4 | Registration for a merger or exchange | Feb 10, 2023 | — |
| 424B4 | Prospectus | Sep 13, 2021 | — |
| S-1/A | Amended registration statement | Sep 7, 2021 | — |
| S-1 | Registration statement | Aug 24, 2021 | — |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLDI (NYSE), CLDWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1855485
- Former names
- Calidi Biotherapeutics, Inc. (until Sep 25, 2026); First Light Acquisition Group, Inc. (until Sep 19, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.